NCT06535308View on ClinicalTrials.gov

BnH-015B Clinical Trial in Moderate Alzheimer's Disease

PHASE1RecruitingINTERVENTIONAL

Enrollment

92

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions

Alzheimer Disease

Interventions

DRUG

BnH-015B 5 mg

Korean / 3 on BnH-015B, 1 on placebo

DRUG

BnH-015B 10 mg

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 20 mg

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 40 mg (Dietary impact)

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 40 mg

Caucasian / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 80 mg

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 160 mg

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 40 mg (MAD)

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 80 mg (MAD)

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 40 mg (Part II)

Korean / 9 subjects

DRUG

BnH-015B 80 mg (Part II)

Korean / 9 subjects

DRUG

BnH-015B Placebo (Part II)

Korean / 6 subjects

Trial Locations (1)

03080

RECRUITING

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

BnH Research

INDUSTRY

NCT06535308 - BnH-015B Clinical Trial in Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter